Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial

Published:2023-03 Issue:3 Volume:81 Page:373-376
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Derebail Vimal K.,Zhu Jing,Crawford Matthew L.,Garnier Julia R.,Martin Karlyn A.,Skinner Sarah,Patel Tejendra,Froment Anne,Sketch Margaret R.,Szeto Andy H.,Patel Sheel M.,Torrice Chad D.,Tiefenbacher Stefan,Adcock Dorothy M.,Grant Russell P.,Key Nigel S.,Crona Daniel J.^ORCID

Publisher

Elsevier BV

Subject

Nephrology

Reference11 articles.

1. Epidemiology and risk factors for venous thrombosis;Cushman;Semin Hematol,2007

2. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease;Kerlin;Clin J Am Soc Nephrol,2012

3. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study;Mahmoodi;Circulation,2008

4. KDIGO 2021 clinical practice guideline for the management of glomerular diseases;Kidney Int,2021

5. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial;Hohnloser;Eur Heart J,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome;Kidney International Reports;2024-07

2. Antikoagulation bei abnormer Nierenfunktion oder Dialyse;Nephrologie aktuell;2024-04

3. Prophylactic Anticoagulation in Nephrotic Syndrome;Kidney360;2023-10